Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Operating Income (2019 - 2025)

Historic Operating Income for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$34.4 million.

  • C4 Therapeutics' Operating Income fell 2183.83% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 876.04%. This contributed to the annual value of -$119.6 million for FY2024, which is 1396.6% up from last year.
  • As of Q3 2025, C4 Therapeutics' Operating Income stood at -$34.4 million, which was down 2183.83% from -$28.5 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Operating Income high stood at -$15.3 million for Q4 2021, and its period low was -$38.3 million during Q4 2022.
  • Its 5-year average for Operating Income is -$29.6 million, with a median of -$29.2 million in 2025.
  • In the last 5 years, C4 Therapeutics' Operating Income crashed by 15101.93% in 2022 and then soared by 4292.48% in 2024.
  • Over the past 5 years, C4 Therapeutics' Operating Income (Quarter) stood at -$15.3 million in 2021, then plummeted by 151.02% to -$38.3 million in 2022, then grew by 2.26% to -$37.4 million in 2023, then dropped by 0.75% to -$37.7 million in 2024, then grew by 8.74% to -$34.4 million in 2025.
  • Its Operating Income was -$34.4 million in Q3 2025, compared to -$28.5 million in Q2 2025 and -$29.2 million in Q1 2025.